Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)
Keywords: HBV; Capsid assembly inhibitor; SAR; GLS4; Pharmacokinetics; Safety evaluation;